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Abstract. A major milestone in modern biology was the complete sequencing of 
the human genome. But it produced a whole set of new challenges in exploring 
the functions and interactions of different parts of the genome. One application 
is predicting disorders based on mining the genotype and understanding how the 
interactions between genetic loci lead to certain human diseases. 
However typically disease phenotypes are genetically complex. They are 
characterized by large, high-dimensional data sets. Also usually the sample size 
is small. 
Recently machine learning and predictive modelling approaches have been 
successfully applied to understand the genotype-phenotype relations and link 
them to human diseases. They are well suited to overcome the problems of the 
large data sets produced by the human genome and its high-dimensionality. 
Machine learning techniques have been applied in virtually all data mining 
domains and have proven to be effective in BioData mining as well. 
This paper describes some of the techniques that have been adopted in recent 
studies in human genome analysis. 
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1 Introduction 
A central challenge in systems biology and medical genetics is to understand how 
interactions among genetic loci contribute to complex phenotypic traits and human 
diseases [1]. A major goal of medical genetics is to determine a set of genetic markers 
which, combined with some common risk factors, can be used to predict an individual’s 
susceptibility to develop certain diseases. Genetic markers can be used to study the 
relation between inherited diseases and its genetic cause. Genetic markers are genes or 
DNA sequences used to identify the presence of specific genes or gene defects. 
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Typically the number of markers p is large and the sample size n is small: “large p small 
n problem”.  
Disease phenotypes are usually genetically complex. A natural first step to tackling 
these formidable tasks is to construct an annotation of the genome, which is to (1) 
identify all functional elements in the genome, (2) group them into element classes such 
as coding genes, non-coding genes and regulatory modules, and (3) characterize the 
classes by some concrete features such as sequence patterns [3].  
Common approaches in genome analysis are statistical methods such as whole-
genome regression models and association testing. These methods regress phenotypes 
on thousands of markers concurrently. They have been improved using for instance 
shrinkage or regularization in Single Nucleotide Polymorphism (SNP) regression 
models, nevertheless they are prone to serious over-fitting problems due to the ratio 
between the number of markers and the available phenotypes. Use of sequencing 
technologies places further challenges because several million of variants per 
individual may need to be taken into account in predictive models [2]. 
In recent studies Machine Learning (ML) techniques have been applied since they 
are capable to deal with the high dimensionality problem in an efficient way. By its 
very nature, genomics produces large, highdimensional datasets that are well suited to 
analysis by machine learning approaches [3]. ML and predictive modelling has proven 
to be an effective way for mining genotype-phenotype relationships. Learning 
techniques are efficient in solving complex biological problems due to characteristics 
such as robustness, fault tolerances, adaptive learning and massively parallel analysis 
capabilities, and for a biological system it may be employed as tool for data-driven 
discovery [4]. 
In recent studies ML techniques in genome analysis have been used for risk 
prediction and treatment of cancer [5,6,7], multiple sclerosis [8], Alzheimer’s disease 
[9,10], diabetes [11] and Legionnaires’ disease [12] to name a few.  
This paper gives an overview of machine learning techniques used in genome wide 
prediction (GWP). 
1.1 Machine learning for genome analysis 
Machine learning (ML) is a branch of Artificial Intelligence (AI). The basic idea is 
to construct a mathematical model based on historic data and apply it to new, unseen 
data. Human learning can be defined as making better decisions in the future based on 
past experiences. Since computers have no experiences they learn from data. A ML 
model learns from historic data to make predictions on new data, for instance predict 
the susceptibility to certain diseases. ML techniques are particularly useful when the 
amount of data is too large to be handled manually or when expert knowledge is 
incomplete.  
ML techniques are divided into supervised, unsupervised and semi-supervised 
methods. For supervised learning algorithms, a given data set is typically divided into 
two parts: training and testing data sets with known class labels [13]. Supervised ML 
are used for classification, for instance to classify regions in the genome into regulatory, 
transcribed and functional sequence regions.  
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Unsupervised ML methods are used for clustering, when the class label is not known. 
They are adopted to understand the underlying structure of data. Genomic loci are 
naturally clustered together according to their similarities, the distribution of features. 
Clustering can be exclusive, if an instance falls into exactly one group, overlapping, if 
some instances belong into two or more groups, or it may be probabilistic. Semi-
supervised techniques are employed when small amounts of labelled data and large 
amounts of unlabelled data exists. Usually in genome analysis supervised methods are 
employed since the class labels are known, for instance protein coding regions and 
regulatory regions.  
Ultimately we want to find a decision function f, that classifies genome loci into 
labels X={x1, x2,…xn}, such that f:X → {E,NE}, predicts if a loci is for instance a 
enhancer E, or not NE. This is a binary classification problem since we have two class 
labels. f is called classifier. If there are more than two class labels, it is a multi-class 
classification problem. For instance if we want to identify regions such as silencers and 
insulators in addition to enhancers and promoters. If we do not have a set of pre-defined, 
discrete values but continuous values, we have a regression problem and f is called a 
regressor or estimator. Here we focus on classification, since we want to associate DNA 
sequences with specific element classes. However, it should be noted that many 
classifiers output the probability Pr, that a region xi with corresponding label yi belongs 
to class j: 
 
 )Pr( jyx ii   (1) 
To find a suitable f we need to: 
1. Decide on an  appropriate model for f, possible models are artificial Neural Networks 
(aNN), naïve Bayes classifier, boosting or Support Vector Machines (SVM) 
2. Find a set of training data, for instance a set of regulatory regions that contain 
enhancers and promoters 
3. An estimate for the classification accuracy such as a loss function 
For task 1, to decide on the appropriate model, several models are trained and the 
one that predicts the label of a region most accurately is chosen. Experience shows that 
no single machine learning scheme is appropriate to all data mining problems [14]. To 
decide which scheme is the most appropriate we need a means of evaluating the trained 
model. Since performance on the training set is no good indicator of performance on 
unseen data, task 3, evaluating the model, is tricky, especially when the set of training 
data from task 2 is small. We need to be able to predict the performance of the model 
on future data and compare it to the estimated performance of the other trained models. 
Cross-validation is one of the most popular evaluation methods in limited-data 
situations. It will be described later in this paper. 
1.1.1 Artificial neural networks. 
Artificial neural networks (ANN) can act as universal approximators of complex 
functions because of their capability of learning linear or nonlinear relationships 
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between predictor variables and responses, including also all sorts of interactions 
between explanatory variables [2]. There are many types of ANN, but in GWP usually 
multilayer ANN are used. Multilayer ANN consist of an input layer, one or more middle 
layers, called hidden layers and an output layer. The input layer is given for instance 
SNP genotype codes, pedigree and nuisance variables as input. 
 A multilayer ANN consists of preceptrons, the neurons, which are 
interconnected through weighted connections, the axons. The basic idea of a perceptron 
is to find a linear function ƒ such that: 
 bxwxf T )(    (2) 
where ƒ (x) > 0 for one class and ƒ (x) < 0 for the other class, and w = (w1, w2, …, 
wm) is the vector of coefficients (weights) of the function, and b is the bias. During 
training the weights and bias are adjusted until prediction accuracy is converging. 
ANN are prone to over-fitting. Over-fitting occurs when the model describes the 
noise or random error instead of the underlying data. An over-fitted model would have 
good training accuracy but poor testing accuracy [3]. Two techniques that are widely 
used for overcoming over-fitting in ANN models are Bayesian regularization and cross-
validated early stopping [2]. 
In recent studies ANNs have been used to study gene-gene interactions for 
biomarkers [18], to model gene-environment interactions [19] and to find splice sites 
in human [20]. 
1.1.2 Naïve Bayesian classifiers 
Naïve Bayesian classifiers are a family of simple, probabilistic classifiers based on 
the Bayes theorem. The term naïve refers to the fact that there is a strong independence 
assumption between the features. The naïve Bayesian classifiers builds a probabilistic 
model of the features and predicts the classification of new, unseen examples. Naïve 
Bayes can use kernel density estimators, which improve performance if the normality 
assumption is grossly incorrect; it can also handle numeric attributes using supervised 
discretization [14]. 
The Bayesian classifier has been applied in analyzing effectors in the genome to 
detect the causative agent of Legionnaires’ disease with an accuracy of more than 90% 
[12]. It has been adopted for analyzing of single nucleotide polymorphism for detecting 
Alzheimer’s disease. Single Nucleotide Polymorphisms (SNPs) are a specific class of 
genomic variation responsible for about 90% of human variability [6]. A high 
classification accuracy has been achieved for the detection of Alzheimer’s disease [9]. 
1.1.3 Boosting 
Boosting is an ensemble learning method. It is often advantageous to take the 
training data and derive several different training sets from it, learn a model from each, 
and combine them to produce an ensemble of learned models [14]. By combining 
several weak learning schemes it is often possible to create a very strong one. If several 
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schemes have been trained, it can be advantageous not to choose the best performing 
one but to combine them all. 
Boosting combines models that complement each other. Boosting has several 
characteristics. The models are of similar type such as decision trees. Boosting is 
iterative, each new model is build based on the performance of the previous model. 
New models are trained in a way that it performs well for instances that were incorrectly 
handled by previous models. Also models are weighted by their confidence and are not 
treated equally. 
Boosting has been applied to GWP in chicken, swine and dairy cattle with similar or 
better predictive ability than Bayes A or G-BLUP [2]. 
1.1.4 Support Vector Machines 
The basic idea behind Support Vector Machines is to find a function that can be 
expressed in terms of a few support vectors and can be applied to non-linear problems. 
It uses linear models to implement non-linear regressions by mapping the input space 
into a higher dimensional feature space using kernel functions [2]. Support Vector 
Machines (SVM) create a feature space or vector space defined by a similarity matrix 
(kernel) and create a hyperplane, an affine decision surface, separating the examples, 
for instance enhancers and promoters, and maximizes the distance from it from the 
closest training samples. SVMs operate by finding a hyper surface in the space of gene 
expression profiles, that will split the groups so that there is largest distance between 
the hyper surface and the nearest of the points in the groups [17]. 
If the training data is linearly separable, then a pair (w, b) exists such that  
wTxi + b ≥ 1, for all xi ∈ P 
wTxi + b ≤ -1, for all xi ∈ N 
 
with the decision rule given by: 
 
  bw
T bxwx
,
)sgn()(  (3) 
 
where w is termed the weight vector and b  the bias (or − b  is termed the threshold) 
[15]. 
SVM have been primarily used for classification, but they can also be used for 
regression. SVM have been successfully applied for instance in predicting cancer-
causing missense variants and achieved a 93% overall accuracy [6] and for analyzing 
gene-gene interactions by investigating SNPs for Type 2 diabetes mellitus (T2D) and 
achieved an accuracy of more than 70% [11]. 
1.1.5 Cross-validation 
Often in genome sequencing the sample size is small and a major challenge is to 
estimate accurately the prediction performance of a ML model. It is in fact not very 
hard to find genetic features that can almost perfectly fit to a small training set but fail 
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to generalize to unseen data, a phenomenon known a s model overfitting [1]. To 
overcome this problem the model has to be tested against an independent data set not 
used in training. Cross-validation is an effective method for predicting the performance 
in a small data situation. n-fold cross-validation divides the data set randomly into n 
folds. n -1 folds are used for training, one fold, the holdout set is used for testing. This 
process is repeated n times such that each of the n folds has been used once as holdout 
set for testing.  
To avoid a class to be overrepresented in one data set, random sampling should be 
done in a way such that each class is represented properly in the training and testing 
set. This procedure is called stratification, and we might speak of stratified holdout [14]. 
However stratification is only a primitive safeguard against uneven representation and 
often leads to over-optimistic results. A more effective method to mitigate this bias is 
to repeat all iterations with different random samples. For each iteration the error rate 
is calculated and averaged at the end of all iterations to yield the overall error rate. 
Usually n is between 5 and 10. Extensive tests on numerous different datasets, with 
different learning techniques, have shown that 10 is about the right number of folds to 
get the best estimate of error, and there is also some theoretical evidence that backs this 
up [14]. 
Cross-validation has been used based on the analysis of SNP. Cross-validation in 
combination with the Bayes classifier achieved a high accuracy for the detection of 
Alzheimer’s disease [9] and combined with SVM for T2D detection [11]. 
2 Discussion 
Genome sequencing remains a challenging task due to the complexity, high-
dimensionality and large size of the human genome. The number of sequences available 
is increasing exponentially [16]. There are challenges inherent to the data, the genome, 
and challenges originating from the analysis methods. 
Complex diseases such as cancer are multi-factorial in nature and interactions among 
genetic loci, epistatic interactions, are believed to be a major contributing factor. There 
exist also increasingly complex interactions between genetic variants and 
environmental factors that may contribute to the disease risk on an individualized basis 
[1]. This suggests that a one variant at a time approach might not be expedient and a 
more holistic approach should be pursued. 
It is often difficult to define the exact span of a genomic region. Biologically it could 
be fuzzy to define exactly where a functional element starts and ends (as in the case of 
an enhancer), and even if the span could be formally defined (as in the case of an RNA 
transcript), it is usually not known prior to machine learning [3].  
The class labels of neighboring genomic regions are not independent. For example, 
if a base is within an intron, the next base should be either within an intron or a splice 
site [3]. 
Several aspects of ML influence the performance of ML techniques and need to be 
considered when evaluating the classifier. Different ML methods handle redundancy 
dramatically differently. For instance the naïve Bayes classifier assumes the input 
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features to be independent from each other for each class, otherwise the redundant 
features could have an undesirable stronger influence on the predictions from the non-
dependent ones. 
In genome analysis the amount of samples, the training data, is often limited, “large 
p small n problem”. There might not be enough training samples to create a model that 
accurately predict class labels. The situation is aggravated if irrelevant features to the 
problem are included. Also there is a high risk of over-fitting. Semi-supervised ML 
techniques are a practical way to alleviate the problem. 
Genomic features often combine different data types, for instance the frequency of 
a feature might be represented by a numeric value and the raw sequence of it as text 
string. One systematic approach to handling mixed data types is to turn each type of 
data into a numerical similarity matrix between the input regions before integrating 
them [3]. 
Currently there are still likely undiscovered genomic element classes given the rapid 
discovery of new classes (such as many non-coding RNAs (ncRNAs)) in recent years 
[3]. In ML terms this means that purely supervised techniques are not suitable. 
Combining several machine learning methods, a technique called ensemble learning, 
has been proposed. For instance boosting or random forests are ensemble learning 
techniques that have been used in genome mining [3,5]. 
To train ML models in a way that yields suitable predictors, each class has to be 
properly represented in the training and in the test data set. This process is called 
stratification. Since genome sample size is often small, having a large enough stratified 
holdout for testing can be difficult. Furthermore negative examples are crucial for ML, 
however often there is limited availability. They are irrelevant for the problem but they 
are crucial for training the model. Availability of more negative samples would be 
highly desirable and finding effective techniques for producing them could be an area 
of further research. 
Feature selection is a key for developing effective predictive models for GWA and 
implementing scalable algorithms for genetic feature selection is crucial for successful 
ML modelling. Further research in the area of computational genetic feature selection 
is essential for building scalable ML-based predictive models. 
Due to the complexity of the problem, more holistic approaches “which take into 
account the complexity of the genotype-phenotype relationships characterized by 
multiple gene-gene and gene-environment interactions [1]” should be pursued in future 
research. ML techniques are well suited for complex problems and large data sets and 
might shed more light into the genotype-phenotype relation as well as other influencing 
factors that lead to complex diseases. 
3 Conclusions 
ML techniques have been adopted in virtually all data analysis domains. ML 
techniques can generate highly complex models. This is particularly advantageous 
when the data to be analyzed is also complex such as for instance eukaryotic genes. 
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In recent years a major paradigm shift in disease treatment towards personalized 
medicine strategies and a network pharmacology, a paradigm which provides a more 
global understanding of drug action in their context of biological networks and 
pathways, has been surfacing. Genomic profiling might lead to tailored personalized 
treatments and help predict a patient’s susceptibility for certain diseases and induce 
early treatment. ML techniques have shown to be well suited to enable these new 
paradigms. In this paper some of the more popular techniques were described, but many 
other techniques have been used in genome analysis. For instance ML techniques based 
on hidden Markov models have become a one of the most popular methods for 
computational gene finding. 
ML techniques are very suited to handle multiple, heterogeneous features. 
Depending on the mathematical form of the model, the different features can be 
integrated in ways from linear combinations to highly nonlinear ones [3]. 
ML techniques can be used to probe drugs for their efficacy against cancer in silico. 
In silico methods to accurately predict the effectiveness of drugs based on the molecular 
making of tumors (i.e. genome, transcriptome) would be a major milestone towards 
personalized therapies for cancer patients based on molecular biomarkers [7]. Machine 
learning-based predictive modeling approaches are well-powered to make the most of 
the exciting functional and genetic screens toward revealing hidden genetic variants 
and their interactions behind cancer and other complex phenotypes [1]. 
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